RNA, 7SL, cytoplasmic 417, pseudogene: A promising RNA target for cancer treatment

Target Name: RN7SL417P

NCBI ID: G107080636

RN7SL417P

Other Name(s): RNA, 7SL, cytoplasmic 417, pseudogene

RNA, 7SL, cytoplasmic 417, pseudogene: A promising RNA target for cancer treatment

The search for new cancer treatments has led to the identification of RNA targets. One of these targets is the RNA molecule known as RN7SL417P. This RNA molecule, classified as RNA, 7SL, cytoplasmic 417, and pseudogene, has been shown to have potential as a drug target or biomarker in cancer treatment.

The RNA molecule RN7SL417P is a 21-kDa protein that is expressed in various cell types, including human breast and ovarian cancer cells. It is located in the cytoplasm and has been shown to play a role in cell signaling, specifically in the regulation of cell adhesion and migration.

One of the key features of RN7SL417P is its cytoplasmic localization. Unlike other proteins that are predominantly expressed in the nucleus, RN7SL417P is primarily found in the cytoplasm. This localization suggests that it may not be a good target for small molecules, which are often used as drug candidates. However, its cytoplasmic localization does make it a potential candidate for targeting agents that can cross the plasmic membrane and interact with it in the cytoplasm.

In addition to its cytoplasmic localization, another feature that makes RN7SL417P a promising target for cancer treatment is its expression in cancer cells. Cancer cells are often characterized by the loss of normal cell proliferation, and this loss is often associated with the development of drug resistance. The expression of RN7SL417P in cancer cells suggests that it may be a good biomarker for monitoring the effectiveness of cancer treatments.

Furthermore, the structure of RN7SL417P has also been reported to be involved in the regulation of cell signaling. Specifically, it has been shown to play a role in the regulation of theNotch signaling pathway, a pathway that is often involved in cancer progression.

The potential benefits of targeting RN7SL417P with small molecules or antibodies are significant. If successful, RN7SL417P could be used to treat various types of cancer, including breast and ovarian cancer. It is also a potential biomarker for monitoring the effectiveness of cancer treatments, which could be used to track the progress of disease and the response to different treatments.

In conclusion, RN7SL417P is a promising RNA target for cancer treatment due to its cytoplasmic localization, expression in cancer cells, and involvement in cell signaling pathways, including the regulation of theNotch signaling pathway. Further research is needed to determine its potential as a drug target or biomarker.

Protein Name: RNA, 7SL, Cytoplasmic 417, Pseudogene

The "RN7SL417P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RN7SL417P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets